Alexion Pharm Inc (ALXN)
Alexion Pharm Inc
NASDAQ:ALXN (7/20/2021, 8:56:13 PM)
After market: 183 +0.5 (+0.27%)182.5
+3.05 (+1.7%)
Company Profile
Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 3,837 full-time employees. The firm is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Company Info
Alexion Pharm Inc
121 Seaport Blvd
Boston MASSACHUSETTS 02210
P: 14752302596.0
CEO: Ludwig N. Hantson
Employees: 3837
Website: https://alexion.com/
ALXN News
4 months ago - BloombergEx-Pharma Executive Avoids Prison for Tipping Pal About MergerA former Alexion Pharmaceuticals Inc. executive avoided jail after pleading guilty to sharing information about the company’s planned purchase of another company in 2020 with a boyhood friend.
2 years ago - Comserve Inc.Wilson Disease Drugs Market Analysis Growth Challenges, Opportunities and Future Developments to 2029
3 years ago - The Motley FoolWill Moderna’s Tenure on the S&P 500 Index Be Short-Lived?It's not likely.
3 years ago - Zacks Investment ResearchAlexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With shares at record-high prices now, very few on Wall Street still see upside in the stock.
3 years ago - Zacks Investment ResearchALXN vs. TECH: Which Stock Is the Better Value Option?ALXN vs. TECH: Which Stock Is the Better Value Option?
ALXN Twits
Here you can normally see the latest stock twits on ALXN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
